Knitting the Threads of Silk through Time: Behçet’s Disease—Past, Present, and Future

Fahd Adeeb,1,2,3,4 Austin G. Stack,2,3,5 and Alexander D. Fraser1,2,3

1Department of Rheumatology, University Hospital Limerick, Limerick, Ireland
2Graduate Entry Medical School, University of Limerick, Limerick, Ireland
3Health Research Institute, University of Limerick, Limerick, Ireland
4Department of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia
5Department of Nephrology, University Hospital Limerick, Limerick, Ireland

Correspondence should be addressed to Fahd Adeeb; fahd_adeeb@yahoo.com

Received 12 June 2017; Accepted 7 August 2017; Published 10 September 2017

In this review article, we explore recent studies that have substantially contributed to our understanding of BD in recent years and have provided new insights into the epidemiology, etiology, immunopathogenesis, clinical manifestations, classification criteria, and management strategies of BD as well as identifying areas for further research.

1. Introduction

Behçet’s disease (BD), also known as the Silk Road disease [1], was first described in the Cyclades island of Kos by Hippocrates in his writings Third Book of Endemic Diseases [2, 3] but remained in relative obscurity for more than two millennia until 1937 when a Turkish dermatologist in Istanbul, Hulusi Behçet, described a trisymptom complex of recurrent aphthous stomatitis, genital ulcers, and iritis in three native Eastern Mediterranean patients and posited a new clinical syndrome [4].

Previously described among populations extending around the ancient Silk Road, a trading route that stretched from the Iberian Peninsula on the southwestern tip of Europe, across Iran, Iraq, and Syria of the Middle East to the Far East, BD has a global distribution and can be seen throughout the world including countries further north and south of the equator (≥60°). The principle morbidity of BD relates to its vascular, ophthalmic, and neurological complications, and if left untreated, it may lead to blindness and death.

In this review article, we explore recent studies that have substantially contributed to our understanding of BD in recent years and have provided new insights into the epidemiology, etiology, immunopathogenesis, clinical manifestations, classification criteria, and management strategies of BD as well as identifying areas for further research.

2. Epidemiology

Behçet’s disease is mainly seen along the ancient Silk Road which stretched from the Far East to the Mediterranean Sea but has an occurrence worldwide. Turkey has the highest prevalence with studies reporting wide prevalence rates between 602 and 20 per 100,000 population, followed by Iran with 68 per 100,000 population (Table I) [5–26]. The frequency increases in a north-to-south manner within the European continent [9, 27]. In Northern Europe, the prevalence ranges from 0.64 to 4.94 per 100,000 population [5–8]. It is noted that the prevalence has increased over time, which may relate to better awareness and/or migration [23, 24].
Table 1: The worldwide prevalence of BD.

| Country/area        | Study (year)               | Patients (n) | Population/participants | Prevalence (per 100,000) |
|---------------------|----------------------------|--------------|-------------------------|--------------------------|
| Northern Europe     |                            |              |                         |                          |
| UK (Yorkshire)      | Chamberlain (1977) [5]      | 32           | 5,000,000               | 0.64                     |
| Scotland            | Jankowski et al. (1992) [6] | 15           | 5,500,000               | 0.3                      |
| Ireland (Dublin)    | Kilmartin et al. (1997) [7] | 24           | 1,058,264               | 2.27                     |
| Sweden (Skane)      | Mohammad et al. (2013) [8]  | 40           | 809,317                 | 4.94                     |
| Europe              |                            |              |                         |                          |
| Germany             | Papoutsis et al. (2006) [9] | 165          | 3,391,344               | 4.87                     |
| France (Paris)      | Mahr et al. (2008) [10]    | 79           | 1,094,412               | 7.1                      |
| Italy (Rome)        | Valesini et al. (1991) [11] | 155          | NA                      | 19                       |
| Greece              | Kaklamani et al. (2000) [12]| 90           | NA                      | 11                       |
| Mediterranean       |                            |              |                         |                          |
| Turkey              |                            |              |                         |                          |
| Tokat               | Baş et al. (2016) [13]     | 14           | 2,325                   | 602                      |
| Kayseri             | Çölgeçen et al. (2015) [14] | 9            | 5,218                   | 170                      |
| Haşha              | Cakir et al. (2004) [15]   | 1            | 4,861                   | 20                       |
| İstanbul            | Azizleri et al. (2003) [16]| 101          | 23,986                  | 420                      |
| Ankara              | İdil et al. (2002) [17]    | 16           | 17,256                  | 110                      |
| Ordu                | Yurdakul et al. (1988) [18]| 19           | 5,121                   | 370                      |
| İstanbul            | Demirhindili et al. (1981) [19]| 4        | 4,940                   | 80                       |
| Mediterranean       |                            |              |                         |                          |
| Iran                | Davatchi et al. (2007) [20] | 7            | 10,291                  | 68                       |
| Egypt               | Assaad-Khalil et al. (1997) [21]| 274    | NA                      | 16                       |
| Jordan              | Madanat et al. (2000) [22] | 200          | NA                      | 27                       |
| Others              |                            |              |                         |                          |
| US (Olmsted County) | Calamia et al. (2009) [23] | 13           | 144,248                 | 5.2                      |
| Japan               | Nakae et al. (1993) [24]   | 3316         | NA                      | 13.5                     |
| Korea               | Bang et al. (2011) [25]    | 15,554       | NA                      | 30.2                     |
| China               | Zhang et al. (2006) [26]   | 1996         | NA                      | 14                       |

Previously thought to have an equal sex distribution, BD appears to have a male preponderance in Turkey [13, 14, 16], the Middle East, and Central Europe [28]; however, females predominate in Northwest Europe [5, 6] and the Far East [24–26, 29, 30]. Certain regional/geographical differences may exist; for example, pathergy phenomenon and ocular lesions are less commonly seen in the West [31–33], while gastrointestinal manifestations are more commonly seen in the Far East [34].

3. Etiology

The cause of BD remains largely unknown but it has been postulated that when a genetically predisposed or susceptible population is exposed to undetermined exogenous agents, this triggers dysregulation of both autoinflammatory and autoimmune responses resulting in multisystem vasculitis with distinct clinical characteristics. However, so far, no microbiologic or external environmental exposure has been consistently identified as a risk factor or trigger [35, 36]. More recently, dysbiosis of gut microbiota characterized by the reduction of the microbiota diversity and composition has been implicated in several autoimmune disorders including diseases outside of the gut [37, 38], and this dysbiosis seems to play a role in the pathogenesis of BD [39, 40].

Association of HLA-B*51 allele is well recognized as the strongest genetic susceptibility gene so far among genetically predisposed BD patients [41, 42]. However, some studies have failed to demonstrate linkage [6, 42, 43], while certain indigenous Amerindians have a high prevalence of HLA-B*51, but with no reported cases of BD [44]. A high level of recombination within the MHC is known to have occurred in these eastern populations before their migration. It was suggested that the disruption of genetic loci in linkage disequilibria within HLA-B*51 might be one reason for the absence of disease in these high HLA-B*51-bearing populations [44].

Centromeric regions including the tumour necrosis factor (TNF) gene and the MHC class I chain-related gene A (MICA) polymorphisms have been the focus of considerable
research, particularly since TNF exerts a profound effect on the immune response, and MICA has a putative role in nonclassical antigen presentation at mucosal surfaces. However, it has become apparent that polymorphic areas in these regions, which are associated with BD, are in fact raised as a consequence of linkage disequilibrium within HLA-B*51 and may provide little independent contribution to disease in HLA-B*51-negative individuals. Thus, in most populations the highest risk factor for BD is still in or close to the HLA-B*51 region [44].

4. Immunopathogenesis

Evidence suggests that a divergent and complex series of interactions and interplay between different cytokines, chemokines, and various components of the host immune system is involved in the pathogenesis of BD [45, 46]. There are several established cytokines such as TNF-α, interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β), IL-6, IL-10, IL-17, and IL-23 known to be involved [45–47]. Furthermore, several "novel" cytokines are now implicated in the pathogenesis of BD including IL-2, IL-12, IL-21, IL-22, IL-33, and IL-37 [45, 48–59]; however, these require further studies to support a definitive role. Some of these findings have been replicated in the genome-wide association studies (GWAS) [60–64]. Moreover, the successful use of some anticytokine therapies in BD patients has provided additional evidence that cytokines play a crucial role in its pathogenesis [45, 46].

There is emerging evidence to support upregulation of chemokines in patients with BD [65–69], and a number of studies have implicated regulatory T cells (Tregs) and gammadelta (δ) T cells in the immunopathogenesis of BD [70–73]. In addition, studies have also supported a role for neutrophil hyperfunction, endothelial cell activation [74–76], and activation of inflamasomes-dependent [77, 78] and JAK/STAT pathways [79, 80], while other studies have demonstrated correlations between autoantibodies such as anti-saccharomyces cerevisiae antibodies (ASCA) and anti-endothelial cell antibodies (AECA) and BD [81–86].

5. Clinical Manifestations

Commonly the symptoms of BD are self-limiting and tend to relapse in an unpredictable manner with differing phenotypes presenting among individuals but certain manifestations such as ocular, vascular, and neurological manifestations may lead to significant morbidity and death. Ideguchi et al. in their study in a Japanese population found that the time between the initial symptoms to the time of diagnosis was 8.6 years [87].

Oral aphthosis is the most common clinical feature and is usually the first manifestation [33]. It is characterized by round to oval ulceration with a white or yellowish necrotic base and surrounded by erythematous halo [88, 89]. It may involve any part of the oral mucosa, frequently the lips, buccal mucosa, tongue, gingiva, palate, and tonsils [33] and can be induced by local trauma such as after dental treatment (mucosal pathergy equivalent) [89]. The rate of recurrence and duration can vary with each attack and the majority of episodes are significantly painful [89]. Genital ulceration is the second most common observed feature of BD [33] and can occur on the scrotum, prepuce, glans, and shaft and tip of the penis in men, while it is typically seen on the vulva (laba majora, labia minora, and mons pubis) and/or intravaginal and cervical areas in women. They can also occur on the perianal, perineal, and groin areas. The ulcers are usually well defined, deep, and often painful and heal slowly with the larger and deeper lesions frequently healing with scarring [89].

The eye is the most common vital organ involved in BD [90] and over two-thirds of patients will develop ocular inflammation, most often bilateral panuveitis or retinal vasculitis [91]. Ocular manifestations include nongranulomatous iridocyclitis, chorioretinitis, or residual lesions suggesting previous iridocyclitis or chorioretinitis such as posterior synechiae, complicated cataracts, lens pigmentation, chorioretinal atrophy, optic nerve atrophy, and secondary glaucoma. The prognosis is worse among patients with posterior segment involvement. Hypopyon in BD classically is nonstick and tends to shift according to the head positioning [92]. Vision loss develops and worsens with each uveitis attack.

Skin manifestations are also one of the most common features of BD and these include but are not limited to erythema nodosum like eruptions, pseudofolliculitis, and papulopustular lesions. Despite being considered as one of the milder symptoms, skin manifestations may contribute to significant morbidity and impact negatively on patients’ quality of life. Vascular BD affects both arteries and veins of all sizes and is more common in men than women [93]. Thrombophlebitis affecting superficial or deep veins is the most common manifestation, while arterial disease is less frequent but a major cause of mortality in BD patients. Neurological manifestations are relatively uncommon and can be classified into parenchymal (an inflammatory meningoencephalitic process with presence of isolated brainstem atrophy as a powerful discriminator) or nonparenchymal (secondary to vascular involvement) [94]. Diagnosis is difficult and often MRI brain (including contrast and MR venogram) and cerebrospinal fluid (evidence of neutrophilia and/or pleocytosis, frequently absent oligoclonal bands, and normal glucose levels) may assist in the diagnosis [94]. Other known manifestations include arthritis/arthralgia, cardiac, gastrointestinal, and laryngeal involvement [33, 95].

Pathergy phenomenon is a nonspecific cutaneous hyperreactivity response to minor trauma. There is large geographical variability in the prevalence of a positive pathergy test reaction [33, 96], and a decline in the positive rate over time has been detected [33, 97]. Positive pathergy testing is as high as up to 77% among patients in the Middle East, around the Mediterranean and the Far East [33, 98], but is less common in Northern European countries and the USA [43, 99–101].

6. Classification Criteria

The diagnosis of BD is clinical but not all symptoms occur simultaneously and the evolution varies among patients as well as among cohorts from different geographical areas.
Furthermore, there is no laboratory test that can be used to make the diagnosis, hence the need for developing diagnostic disease criteria. The first diagnostic criteria in BD were devised in 1946 [102, 103], and now there are at least 17 diagnostic criteria available [103].

In 1990, the International Study Group (ISG) set the classification criteria [104] which were presented at the 6th International Conference on BD in Paris (1993) where recurrent oral aphthosis three or more times in a year is mandatory, with the presence of any two of the following: genital ulceration, ocular or cutaneous manifestations, or skin pathergy. It is important to note that the criteria are applicable only if no other clinical explanation is present. Despite being of high specificity and recognizing its contribution to assisting comparison among cohorts across the world in a more standardized manner, the criteria raised several important issues including the exclusion of minority groups of likely BD patients without the oral aphthosis and demonstrating relatively lower sensitivity in comparison to other diagnostic criteria [105].

To overcome these issues, in 2004 during the 11th International Conference on BD in Antalya, Turkey, The International Team for the Revision of the ISG criteria was formed involving 27 countries for the revision, proposal, and creation of the newer international criteria for BD (ICBD), which was then revised in 2010 [103]. These criteria are based on a point basis, oral aphthosis is not mandatory, and vascular and neurological manifestations were added to the existing five items of the ISG criteria. While oral aphthosis, genital ulceration, and eye manifestations were given two points, other remaining items were given one point each; getting four or more points confirms the diagnosis. It demonstrates improved sensitivity (97% versus 77.5%), a similar specificity (97% versus 99%), and better accuracy (97 versus 87%) when compared to the ISG criteria [103].

7. Current Management Strategies

Effective long-term management in BD patients is often challenging and requires a coordinated multidisciplinary approach. The cornerstone of treatment in systemic BD includes corticosteroids together with steroid-sparing agents (conventional immunomodulators and/or biological therapies) tailored upon the pattern and severity of patient’s symptoms, mainly to achieve rapid resolution of inflammatory attacks, prevention of relapsing episodes, preservation of vital organs, and overall improvement in patients’ quality of life.

7.1. Conventional Treatments

7.1.1. Corticosteroids. Topical steroid therapy such as triamcinolone oral paste with or without topical anesthetics has been shown to be very useful for oral aphthosis in BD [106, 107]. Short courses of systemic oral or depot corticosteroids are particularly useful and effective in oral aphthosis resistant to topical treatment [108, 109] and controlling erythema nodosum especially in female BD patients [110]. High-dose pulsed intravenous methylprednisolone is reserved for patients with threatened vital-organ function. The European League Against Rheumatism (EULAR) task force recently in June 2016 presented their updated recommendations for managing BD at the 17th Annual European Congress of Rheumatology in London and recommended systemic corticosteroid as a combination therapeutic option in inflammatory ocular, vascular (including arterial aneurysms and acute deep vein thrombosis), gastrointestinal, or nervous system involvement [111]. Prolonged and frequent use of systemic corticosteroid however is associated with various unfavorable side effects.

7.1.2. Colchicine. Being one of the oldest known drugs, colchicine has been proven to be beneficial in several randomized controlled trials in the less severe manifestations of BD patients including arthralgia, erythema nodosum, and genital ulcers [112, 113]. The EULAR task force in 2016 also recommended colchicine as first-line treatment for arthritis in BD patients [111]. Its early use however does not decrease the need to use immunosuppressive drugs in the long term [114].

7.1.3. Conventional Immunomodulators. Frequently the additional use of a conventional immunomodulator as adjunctive or as steroid-sparing therapy is required. This is of utmost importance especially in countries with limited access to biological therapy. Agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have been shown to be beneficial [115–121] to induce and maintain remission. Cyclosporine and thalidomide are also options; however, cyclosporine has been strongly associated with neurological complications [122, 123], while thalidomide is highly neurotoxic and teratogenic and should be used with extreme caution if at all in women of childbearing age now that more modern therapies are available [124].

7.2. Biological Therapy. Emerging insights into the immunopathogenesis of BD have led to novel and more specific therapeutic targets. The advent of biological therapies has revolutionized the treatment of BD offering more tailored therapies resulting in significantly better disease control and prolonged remission in the majority of patients. This is an area that is rapidly expanding and is currently being robustly explored by both clinicians and researchers across the globe.

Anti-TNFs have been shown to be remarkably effective and relatively safe [125, 126]. Nonetheless, despite two decades of experience in rheumatological conditions such as BD, there are still many debatable issues surrounding their use including the following: (1) When to start treatment and the duration of treatment and does early use modulate the subsequent clinical course? (2) Is it beneficial to coadminister conventional nonbiologic DMARDs such as methotrexate to reduce immunogenicity and to reduce secondary failure rates? (3) The infection rates for combination therapy are especially high in elderly patients. (4) How effective are the “newer” anti-TNFs such as certolizumab pegol and golimumab? (5) Head-to-head studies to compare the safety and efficacy of different groups of biological agents, especially anti-TNF and interferon-2-alpha as monotherapy or
in combination with conventional immunomodulators, are required.

Interferons (IFNs) are the oldest known cytokine and type-I IFN has been used as one of the treatment modalities in BD as early as the mid-1980s [127, 128]. There is gathering evidence, especially in more recent times, documenting the successful use of both IFN-α-2a and -2b with acceptable toxicity profiles in many clinical trials [129–133]. Contrary to IL-1α, IL-1β is not present in cells from healthy individuals [134] and has been demonstrated to be one of the principal highly active proinflammatory cytokines involved in the pathogenesis of BD [45–47]. There is emerging theoretical evidence for the use of IL1β-regulating antibody agents such as Gevokizumab [135, 136], Anakinra [137–140], and Canakinumab [141–144] in BD, and another orphan drug from this group Rilonacept has been successfully used in other autoinflammatory syndromes [145, 146].

Despite looking promising in the treatment of neuro-BD [147–152], the use of IL-6 blockade-Tocilizumab has yielded less convincing results than anticipated [152–155] and a controlled clinical trial for further evaluation of this biological agent has been terminated due to low enrollment [156]. Another humanized monoclonal antibody of IgG1 depleted antibodies-12/23 monoclonal antibody-BD [147–152], the use of IL-6 blockade-Tocilizumab has been successfully used in refractory BD [157–159]. Other biological agents that are currently or have previously been considered worthy of consideration in the treatment of BD include the IL-12/23 monoclonal antibody-Ustekinumab [160, 161], B-cell depletion antibodies-Rituximab [162–166], Belimumab, and the competitive binding to CD80 and CD86 costimulator antibody-Abatacept which is currently undergoing an open-label clinical trial in the treatment of mucocutaneous manifestations of BD [167].

There are also “less successful” biological agents in BD: the IL-17A blockade by subcutaneous (SC) Secukinumab therapy failed to meet its primary endpoints in three randomized controlled clinical trials which involved 118 Bechet's uveitis patients [168]; however, Letko et al. [169] argued that the dose and the mode of administration may have been a confounding factor and suggested in their proof-of-concept study a higher dose and a different route of administration of Secukinumab (from 300 mg SC to intravenous administration of 30 mg/kg and 10 mg/kg). Another monoclonal antibody Daclizumab, an IL-2 receptor antagonist, also failed to demonstrate efficacy in Bechet's uveitis patients compared to placebo [170] despite demonstrating potent efficacy in many previous studies for other causes of noninfectious uveitis [171–173], while evidence for treatment with intravitreal Bevacizumab, a vascular endothelial growth factor A antibody to treat inflammatory ocular manifestations, has been conflicting [174–178].

7.3. Novel Nonbiologic Small Molecules. Apremilast, a novel small molecule that selectively inhibits phosphodiesterase 4 (PDE4) which is currently approved for psoriasis and psoriatic arthritis, has been shown in a randomized, double blind, placebo-controlled phase 2 study to be effective in treating oral ulcers in BD patients [179]. It is currently undergoing subsequent phase 3 trials. The demonstration of Janus kinase-1/signal transducers and activators of transcription-3 (JAK1/STAT3) signaling pathway activation in BD [79] suggests a potential role for JAK inhibitors (Jakinibs) as a possible next-generation therapeutic modality in the management of BD.

8. Controversies, Conundrums, and Chasms: Prospects for Further Research

BD has been the subject of extensive investigation since its first formal description approximately 80 years ago. Despite best efforts, controversies continue to exist and several questions in many aspects of BD remain unanswered. The 17th International Conference on BD held in Matera, Italy, in September 2016 was a unique opportunity to reflect on the residual challenges that remain in BD and also to highlight new advances in research from the scientific community across the world.

The main areas where controversies continue to exist relate to (1) diagnostic criteria, (2) immunopathogenesis and the search for biomarkers, (3) regional and geographical phenotypic and genotypic variability, and (4) therapeutic considerations including the use of biological therapies and the role of anticoagulation in thrombosis.

One of the major challenges still faced by clinicians is the diagnostic dilemma due to the wide spectrum or heterogeneity of disease manifestations with varying severity, the unpredictable relapsing and remitting episodes of most patients, and the variable chronological evolution of symptoms between different individuals. Despite recognizing mucocutaneous lesions as the hallmark of the disease with ocular inflammation and skin lesions considered part of the major symptoms, a discreet subset of patients manifests other less common yet important characteristics such as vascular, neurological, gastrointestinal, and laryngeal disease. Besides the controversy regarding the optimal management approach among this discreet subset of patients, these infrequent manifestations may lead to significant delay in diagnosis resulting in irreversible organ damage for the patient.

A closely related issue that remains a research enigma is the lack of sensitive and specific diagnostic laboratory tests to confirm or support the final diagnosis of BD. Until we discover such biomarkers, the burden of diagnosis remains with the clinician's ability to recognize and collate a diverse spectrum of presenting manifestations. A substantial number of patients with BD remain undiagnosed for many years resulting in a significant increase in morbidity, disability, and worsening quality of life.

One possible solution to this dilemma is to broaden the classification criteria combining both objective clinical indicators and biomarkers. However, despite the emergence of a number of potential candidate biomarkers, there is still a lack of sufficient evidence to support their implementation and incorporation into the contemporary classification criteria. In the era of precision medicine, this area provides a significant opportunity for improvement in the diagnostic criteria and to find early predictors to detect cohorts with a severe aggressive disease phenotype. Better understanding of disease pathways and the continuous search for signature markers may provide
novel insights into early detection of the disease in the future and providing potential targets for novel therapeutic agents so patients may be treated with the best treatment option in a timely manner.

One of the groundbreaking discoveries of late is the recognition that BD may be diagnosed solely based on ocular findings alone in the absence of systemic manifestations [90] using the state-of-the-art imaging technologies, and this is extremely important as ocular manifestation may be the first presenting manifestations in 10–15% of BD patients [180]. The ultimate goal in eye disease is to sustain remission with preservation of vision [91]. Recent studies support earlier and more frequent consideration for biological therapy in Behçet’s uveitis [91] but questions remain regarding when to use them in patients with uveitis alone and with classical uveitis characteristics but not fulfilling the international criteria for BD. Steroids, while able to rapidly control acute flares, are not able to reduce recurrence rates and their prolonged use is associated with serious side effects.

Recent attention has also focused on the presence of racial, geographical, or regional predilection in phenotypic heterogeneity and genetic variance. Despite some well-documented evidence from endemic areas, the advancement in epidemiological understanding in nonendemic areas especially Northern European countries has been particularly difficult. This is probably one of the most perplexing problems and reflects a lack of detailed epidemiological studies in the so-called nonendemic regions across the globe.

BD is generally described as a polygenic disease; however, family clustering in BD has been described in the literature [181–185]. There is an aberrant subset of BD that carries autosomal-dominant traits highlighting a different pathway in disease pathogenesis. Several candidate gene mutations have been discovered so far including MEFV/TLR4 mutations [186] and more recently TNFAIP3 mutations [187, 188] suggesting several different possible underlying mechanisms to induce inflammation from these mutations including the more recent concept of haploinsufficiency of A20 (HA20) [189]; however, data are still scarce and limited. Targeted next-generation exome sequencing which has the ability to generate millions of short reads of sequence within a short period of time looks promising in novel gene discovery and may provide answers to many questions in the future including how broad these spectrum of disorders are and if there are many other mutations that can cause similar phenotypic picture.

While nonbiological DMARD agents such as thalidomide, methotrexate, azathioprine, and cyclosporine may provide some benefit to these patients, they carry a higher side-effect profile. In this cutting edge era, interferon alpha-2a and TNF have been proven in many instances to be more effective and safer. Newer treatment paradigms showing promising results include ustekinumab, canakinumab, apremilast, tocilizumab (especially in neuro-BD), and brodalumab (for severe mucocutaneous manifestations) and many are undergoing clinical trials. Gevokizumab despite failing to achieve its primary endpoint, which was time to a first ocular exacerbation in a phase III study, may still be effective in preservation of visual acuity, inducing less severe exacerbations and lower incidence of macula edema, and is currently undergoing 2 further trials. However, access to biological agents may be the limiting factor in many countries and it will be important to identify patients who may be resistant to certain therapies and those who will benefit the most from a particular intervention. Head-to-head trials involving the newer and most current agents rather than placebo-controlled should be undertaken in patients with systemic disease or with vital-organ involvement due to the known grave irreversible consequences in untreated or inadequately treated patients.

A question that has been long debated is whether or not to anticoagulate patients with vascular thrombosis. So far, the decision regarding the use of concomitant anticoagulation with the more definitive glucocorticoids and immunosuppressive treatment is based upon individual consultant opinion and retrospective studies [190]. Due to the paucity of evidence, and until randomized controlled trial tests the efficacy of anticoagulation strategies, this question remains unanswered [190]. Caution is needed especially in the rare yet lethal condition known as Hughes-Stovin syndrome where patients have a combination of pulmonary artery aneurysm and deep vein thrombosis. Immunosuppressive therapy remains the mainstay of treatment in vascular BD to induce remission, prevent further relapse, and improve patients’ survival.

Pregnancy can pose a major challenge in BD as the evidence regarding the effect of BD on pregnancy and vice versa is limited. The disease course varies and is difficult to predict during pregnancy [191–193]. Despite a study demonstrating a lower proportion of flares in pregnant BD patients treated with colchicine [194] and another study observing no increased rate of pregnancy-related complications in BD patients [194, 195], several other studies have demonstrated higher miscarriage rates [196, 197], caesarian section rates [196], and smaller babies [197] in BD patients. Other potential issues should also be addressed in pregnancy and in particular the management of pregnant BD patients with known thrombotic tendencies.

In this review, we highlight recent advances in our scientific understanding of BD and shed new insights into diagnostic and treatment strategies. Despite the increase in published scientific literature on BD and the growing interest of a global research community, many aspects of BD remain enigmatic and controversial. Ironically, these deficits in our knowledge serve as a stimulus and challenge to the global scientific community to seek answers to these research questions through national and international collaborations. There is a pressing need for international epidemiological studies of BD with geographical and ethnic mapping, more basic science discoveries to unravel the complex immunopathogenesis, innovation in biomarker discovery to improve diagnostic yield, and large-scale randomized controlled trials to assess therapeutic benefit of current and emerging therapies. Behçet’s disease, the Silk Road disease, has challenged the scientific and clinical communities to come together with a cohesive strategy to foster greater understanding of this rare disease in order to improve patient outcomes.
Conflicts of Interest

All authors have no conflicts of interest to report.

References

[1] S. Ohno, M. Ohguchi, S. Hirose, H. Matsuda, A. Wakisaka, and M. Aizawa, "Close association of HLA-Bw51 with Behçet's disease," Archives of Ophthalmology, vol. 100, no. 9, pp. 1455–1458, 1982.

[2] G. Pasero and P. Marson, "Hippocrates and rheumatology," Clinical and Experimental Rheumatology, vol. 22, pp. 687–689, 2004.

[3] A. Feigenbaum, "Description of Behçet's syndrome in the Hippocratic third book of endemic diseases," The British Journal of Ophthalmology, vol. 40, pp. 355–356, 1956.

[4] H. Behçet, "über rezidivierende aphthöse durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien," Dermatol Wochenschr, vol. 105, pp. 1152–1157, 1937.

[5] M. A. Chamberlain, "Behçet's syndrome in 32 patients in Yorkshire," Annals of the Rheumatic Diseases, vol. 36, 491 pages, 1977.

[6] J. Jankowski, I. Crombie, and R. Jankowski, "Behçet's syndrome in Scotland," Postgraduate Medical Journal, vol. 68, pp. 566–570, 1992.

[7] D. J. Kilmartin, A. Finch, and R. W. Acheson, "Primary association of HLA-B51 with Behçet's disease in Ireland," British Journal of Ophthalmology, vol. 81, no. 8, pp. 649–653, 1997.

[8] A. Mohammad, T. Mandl, G. Sturfelt, and M. Segelmark, "Incidence, prevalence and clinical characteristics of Behçet's disease in southern Sweden," Rheumatology, vol. 52, no. 2, pp. 304–310, 2013.

[9] N. G. Papoutsis, M. B. Abdel-Naser, A. Altenberg, H. Orawa, I. Potter, L. Krause et al., "Prevalence of Adamantias-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey," Clinical and Experimental Rheumatology, vol. 24, supplement 42, S125 pages, 2006.

[10] A. Mahr, L. Belarbi, B. Wechsler et al., "Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration," Arthritis and Rheumatism, vol. 58, no. 12, pp. 3951–3959, 2008.

[11] G. Valesini, P. Pivetti Pezzi, G. Catarinelli, M. Accorinti, and R. Priori, "Clinical manifestations of Behçet's disease in Italy: study of 155 patients at Rome University," in Behçet's Disease Basic and Clinical Aspects, J. D. O'Duffy and E. E. Kokmen, Eds., pp. 279–289, Marcel Dekker Inc, New York, USA, 1991.

[12] V. G. Kaklamani, N. Markomichelakis, G. Vaiopoulos, S. Papazoglou, and P. Kaklamanian, "Clinical features of Adamantias-Behçet's Disease in Greece," in Behçet's Disease, D. Bang, E. Lee, and S. Lee, Eds., pp. 56–59, Design Mecca Publishing, Seoul, South Korea, 2000.

[13] Y. Baş, H. Y. Seçkin, G. Kalkan et al., "Investigation of Behçet's disease and recurrent aphthous stomatitis frequency: the highest prevalence in Turkey," Balkan Medical Journal, vol. 33, no. 4, pp. 390–395, 2016.

[14] E. Çölteşen, K. Özurt, A. Ferahbaj et al., "The prevalence of Behçet's disease in a city in Central Anatolia in Turkey," International Journal of Dermatology, vol. 54, no. 3, pp. 286–289, 2015.

[15] N. Cakir, E. Dervis, O. Benian, O. N. Pamuk, N. Sonmezates, R. Rahimoğlu et al., "Prevalence of Behçet's disease in rural western Turkey: a preliminary report," Clinical and Experimental Rheumatology, vol. 22, supplement 34, pp. 553–555, 2004.

[16] G. Azizlerli, A. A. Köse, R. Sarica et al., "Prevalence of Behçet's disease in Istanbul, Turkey," International Journal of Dermatology, vol. 42, no. 10, pp. 803–806, 2003.

[17] A. Idil, A. Gürler, A. Boyvat et al., "The prevalence of Behçet's disease above the age of 10 years: the results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey," Ophthalmic Epidemiology, vol. 9, no. 5, pp. 325–331, 2002.

[18] S. Yurdakul, I. Gunaydin, Y. Tuzun et al., "The prevalence of Behçet's syndrome in a rural area in northern Turkey," Journal of Rheumatology, vol. 15, no. 5, pp. 820–822, 1988.

[19] O. Demirhindö, H. Yazıcı, P. Binyildiz, N. Dayioglu, Y. Tuzun, and M. Altac, "The prevalence of Behçet's disease in Fener village (Silivri, Istanbul) and its surroundings," Cerrahpasa Tip Fak Derg, vol. 12, pp. 509–514, 1981 (Turkish).

[20] F. Davatchi, A.-R. Jamshidi, A. T. Banihashemi et al., "Prevalence of Behçet's disease in Iran: A WHO-ILAR COPCORD stage I study," APLAR Journal of Rheumatology, vol. 10, no. 3, pp. 239–243, 2007.

[21] S. H. Assaad-Khalil, F. A. Kamel, and E. A. Ismail, "Starting a regional registry for patients with Behçet's disease in North West Nile Delta region in Egypt," in Behçet's Disease, M. Hamza, Ed., pp. 173–176, Pub Adhoua, Tunisia, 1997.

[22] W. Madanat, F. Fayyad, H. Zureikat, D. Verity, J. Narr, R. Vaughan et al., "Influence of sex on Behçet's Disease in Jordan," in Behçet's Disease, D. Bang, E. Lee, and S. Lee, Eds., pp. 90–93, Design Mecca Publishing, Seoul, South Korea, 2000.

[23] K. T. Calamia, F. C. Wilson, M. Icen, C. S. Crowson, S. E. Gabriel, and H. M. Kremer, "Epidemiology and clinical characteristics of Behçet's disease in the USA: a population-based study," Arthritis Care and Research, vol. 61, no. 5, pp. 600–604, 2009.

[24] K. Nakae, F. Masaki, T. Hashimoto, G. Inaba, M. Mochizuki, and T. Sakane, "Recent epidemiological features of Behçet's disease in Japan," in International Congress Series 1037, B. Wechsler and P. Godeau, Eds., pp. 145–151, Excerpta Medica, Amsterdam, Netherlands, 1993.

[25] D. Bang, E. S. Lee, and S. Lee, "Asian Skin and Skin Diseases: Special Book of the 22nd World Congress of Dermatology," in Behçet's Disease, H. C. Eun, S. C. Kim, and W. S. Lee, Eds., pp. 313–325, MEDrang Inc, Seoul, South Korea, 2011.

[26] Z. Zhang, J. Peng, X. Hou, and Y. Dong, "Clinical manifestations of Behçet's disease in Chinese patients," APLAR Journal of Rheumatology, vol. 9, no. 3, pp. 244–247, 2006.

[27] I. Olivieri, P. Lecese, A. Padula, A. Nigro, C. Palazzi, M. Gilio et al., "High prevalence of Behçet's disease in southern Italy," Clinical and Experimental Rheumatology, vol. 31, supplement 77, no. 3, pp. 28–31, 2013.

[28] N. G. Bonitsis, L. B. Luong Nguyen, M. P. LaValley et al., "Gender-specific differences in Adamantias-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature," Rheumatology (Oxford, England), vol. 54, no. 1, pp. 121–133, 2015.

[29] T. Saylan, C. Mat, I. Fresko, and M. Melikoglu, "Behçet's disease in the Middle East," Clinics in Dermatology, vol. 17, no. 2, pp. 209–223, 1999.

[30] D. Bang, S. Oh, K.-H. Lee, E.-S. Lee, and S. Lee, "Influence of sex on patients with Behçet's disease in Korea," Journal of Korean Medical Science, vol. 18, no. 2, pp. 231–235, 2003.
[31] H. Yazici, M. A. Chamberlain, and Y. Tuzun, "A comparative study of the pathergy reaction among Turkish and British patients with Behcet's disease," *Annals of the Rheumatic Diseases*, vol. 43, no. 1, pp. 74–75, 1984.

[32] M. Muhaya, S. Lightman, E. Ikeda et al., "Behcet's disease in Japan and in Great Britain: a comparative study," *Ocular Immunology and Inflammation*, vol. 8, no. 3, pp. 141–148, 2000.

[33] F. Davatchi, F. Shahram, C. Chams-Davatchi et al., "Behcet's disease: from east to west," *Clinical Rheumatology*, vol. 29, no. 8, pp. 823–830, 2010.

[34] S. Yurdakul and H. Yazici, "Behcet's syndrome," *Best Practice and Research: Clinical Rheumatology*, vol. 22, no. 5, pp. 793–809, 2008.

[35] M. Galeone, R. Colucci, A. M. D'Erme, S. Moretti, and T. Lotti, "Potential infectious etiology of Behcet's disease," *Pathology Research International*, vol. 2012, Article ID 595380, 4 pages, 2012.

[36] G. Hatemi and H. Yazici, "Behcet's syndrome and microorganisms," *Best Practice and Research: Clinical Rheumatology*, vol. 25, no. 3, pp. 389–406, 2011.

[37] N. Cerf-Bensussan and V. Gaboriau-Routhiau, "The immune system and the gut microbiota: friends or foes?" *Nature Reviews Immunology*, vol. 10, no. 10, pp. 735–744, 2010.

[38] D. J. Cua and J. P. Sherlock, "Autoimmunity's collateral damage: gut microbiota strikes 'back'," *Nature Medicine*, vol. 17, no. 9, pp. 1055-1056, 2011.

[39] C. Consolandi, S. Turroni, G. Emmi et al., "Behcet's syndrome patients exhibit specific microbiome signature," *Autoimmunity Reviews*, vol. 14, no. 4, pp. 269–276, 2015.

[40] J. Shimizu, T. Kubota, and E. Takada, "Bifidobacteria abundance-featured gut microbiota compositional change in patients with behcet's disease," *PloS ONE*, vol. 11, no. 4, Article ID e0153746, 2016.

[41] A. Gul and S. Ohno, "HLA-B*51 and Behcet's Disease," *Ocular Immunology & Inflammation*, vol. 20, pp. 37–43, 2012.

[42] M. Piga and A. Mathieu, "Genetic susceptibility to Behcet's disease: role of genes belonging to the MHC region," *Rheumatology*, vol. 50, no. 2, Article ID keq331, pp. 299–310, 2011.

[43] F. Adeeb, A. Ugwoke, A. G. Stack, and A. D. Fraser, "Associations of HLA-B Alleles with Behcet's disease in Ireland," *Clinical and Experimental Rheumatology*, vol. 35, supplement 104, pp. 22–23, 2017.

[44] D. H. Verity, J. E. Marr, S. Ohno, G. R. Wallace, and M. R. Stanford, "Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives," *Tissue Antigens*, vol. 54, no. 3, pp. 213–220, 1999.

[45] F. Adeeb, M. U. Khan, A. G. Stack, and A. D. Fraser, "Etiology, Immunopathogenesis and Biomarkers in Behcet's disease," in *Behket's Disease*, Gönül M. and S. P. K. Durmazlar, Eds., Intech.

[46] A. Güll, "Pathogenesis of behcet's disease: autoimmune inflammatory features and beyond," *Seminars in Immunopathology*, vol. 37, no. 4, pp. 413–418, 2015.

[47] Z. Y. Zhou, S. L. Chen, N. Shen, and Y. Lu, "Cytokines and Behcet's Disease," *Autoimmunity Reviews*, vol. 11, no. 10, pp. 699–704, 2012.

[48] P. Türkcüoğlu, Y. O. Arat, E. Kan et al., "Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease," *Ocular Immunology and Inflammation*, vol. 24, no. 3, pp. 313–318, 2016.

[49] N. Akdeniz, M. Esrefoglu, M. S. Kekel, A. Karakuzu, and M. Atasoy, "Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease," *Annals of the Academy of Medicine Singapore*, vol. 33, no. 5, pp. 596–599, 2004.

[50] Z. M. Akkurt, M. Bozkurt, D. Ucmak et al., "Serum cytokine levels in Behcet's disease," *Journal of Clinical Laboratory Analysis*, vol. 29, no. 4, pp. 317–320, 2015.

[51] G. Geri, B. Terrier, and M. Rosenzweig, "Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease," *Journal of Allergy and Clinical Immunology*, vol. 128, no. 3, pp. 655–664, 2011.

[52] T. Cai, Q. Wang, Q. Zhou et al., "Increased expression of IL-22 is associated with disease activity in Behcet's disease," *PloS ONE*, vol. 8, no. 3, Article ID e59009, 2013.

[53] M. Cordero-Coma, S. Calleja, E. Rodriguez, M. Franco, and J. G. Ruiz De Morales, "Serum cytokine profile in adalimumab-treated refractory uveitis patients: decreased IL-22 correlates with clinical responses," *Ocular Immunology and Inflammation*, vol. 21, no. 3, pp. 212–219, 2013.

[54] K. Hamzaoui, E. Bouali, and K. Hamzaoui, "Interleukin-33 and Behcet disease: another cytokine among others," *Human Immunology*, vol. 76, no. 5, pp. 301–306, 2015.

[55] K. Hamzaoui, A. Borhani-Haghighi, W. Kaabachi, and A. Hamzaoui, "Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines," *Cellular and Molecular Immunology*, vol. 11, no. 6, pp. 613–616, 2014.

[56] D.-J. Kim, S.-Y. Baek, M.-K. Park et al., "Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with behcet's disease," *Journal of Korean Medical Science*, vol. 28, no. 8, pp. 1145–1153, 2013.

[57] E. Bouali, W. Kaabachi, A. Hamzaoui, and K. Hamzaoui, "Interleukin-37 expression is decreased in Behcet's disease and is associated with inflammation," *Immunology Letters*, vol. 167, no. 2, pp. 87–94, 2015.

[58] Z. Ye, C. Wang, A. Kjikstra, X. Zhou, and P. Yang, "A possible role for interleukin 37 in the pathogenesis of Behcet's disease," *Current Molecular Medicine*, vol. 14, no. 4, pp. 535–542, 2014.

[59] K. Hamzaoui and A. Hamzaoui, "The anti-inflammatory activity of Interleukin-37 in Behcet's disease," *Inflamm & Cell Signal*, vol. 3, e1452 pages, 2016.

[60] E. F. Remmers, F. Cosan, Y. Kirino et al., "Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease," *Nature Genetics*, vol. 42, no. 8, pp. 698–702, 2010.

[61] N. Mizuki, A. Meguro, M. Ota et al., "Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci," *Nature Genetics*, vol. 42, no. 8, pp. 703–706, 2010.

[62] J. H. Kappen, C. Medina-Gomez, P. M. Van Hagen et al., "Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behcet Disease," *PloS ONE*, vol. 10, no. 3, Article ID e0119085, 2015.

[63] Z. Wu, W. Zheng, J. Xu, F. Sun, H. Chen, P. Li et al., "IL10 polymorphisms associated with Behcet's disease in Chinese Han," *Hum Immunol*, vol. 75, pp. 271–276, 2014.

[64] J. M. Xavier, F. Shahrour, F. Davatchi et al., "Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease," *Arthritis and Rheumatism*, vol. 64, no. 8, pp. 2761–2772, 2012.

[65] A. M. Abu El-Asrar, S. S. Al-Obeidan, D. Kangave et al., "CXC chemokine expression profiles in aqueous humor of
patients with different clinical entities of endogenous uveitis," Immunobiology, vol. 216, no. 9, pp. 1004–1009, 2011.

[66] N. Ambrose, E. Khan, R. Ravindran et al., “The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-γ/CXCL10 IP-10 pathway,” Clinical and Experimental Immunology, vol. 181, no. 3, pp. 427–433, 2015.

[67] S. P. K. Durmazlar, G. B. Ulkar, F. Eskioglu, S. Tatlıcan, A. Mert, and A. Akgül, “Significance of serum interleukin-8 levels in patients with Behçet's disease: high levels may indicate vascular involvement,” International Journal of Dermatology, vol. 48, no. 3, pp. 259–264, 2009.

[68] H. T. E. Özer, E. Erken, R. Gunesacar, and O. Kara, “Serum RANTES, MIP-1α, and MCP-1 levels in Behçet's disease,” Rheumatology International, vol. 25, no. 6, pp. 487-488, 2005.

[69] I. Kŏkçan, D. Turgut, N. F. Ilhan, and D. Çiçek, “The levels of serum chemokines in patients with Behçet's disease,” Turkish Journal of Medical Sciences, vol. 42, pp. 1105–1110, 2012.

[70] E. Gündüz, H. Üsküdar Tekе, N. Sule Yaşar Bilge et al., “Regulatory T cells in Behçet's disease: Is there a correlation with disease activity? Does regulatory T cell type matter?” Rheumatology International, vol. 33, no. 12, pp. 3049–3054, 2013.

[71] Y. Nanke, S. Kotake, M. Goto, H. Ujihara, M. Matsubara, and N. Kamatani, “Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet's disease before ocular attack: a possible predictive marker of ocular attack,” Modern Rheumatology, vol. 18, no. 4, pp. 354–358, 2008.

[72] A. Clemente, A. Cambra, I. Munoz-Saă et al., “Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Behçet's disease patients and healthy controls,” Immunology Letters, vol. 129, no. 2, pp. 57–63, 2010.

[73] G. Parlakgül, E. Guney, B. Erer et al., “Expression of regulatory receptors on γδ T Cells and their cytokine production in Behçet's disease,” Arthritis Research and Therapy, vol. 15, no. 1, article R15, 2013.

[74] M. Becatti, G. Emmi, E. Silvestri et al., “Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease,” Circulation, vol. 133, no. 3, pp. 302–311, 2016.

[75] M. Yuksel, A. Yildiz, M. Oyrunlu et al., “Novel markers of endothelial dysfunction and inflammation in Behçet's disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio,” Clinical Rheumatology, vol. 35, no. 3, pp. 701–708, 2016.

[76] C. Ozturk, S. Balta, I. Balta et al., “Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with Behçet disease without cardiovascular involvement,” Angiology, vol. 66, no. 3, pp. 291–296, 2014.

[77] E. H. Kim, M.-J. Park, S. Park, and E.-S. Lee, “Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease,” Journal of Inflammation (United Kingdom), vol. 12, no. 1, article 41, 2015.

[78] L. Liang, X. Tan, Q. Zhou et al., “IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome- dependent pathways is involved in ocular behçet's disease,” Investigative Ophthalmology and Visual Science, vol. 54, no. 1, pp. 402–414, 2013.

[79] A. Tulunay, M. G. Dozmorov, F. Ture-Ozdemir et al., “Activation of the JAK/STAT pathway in Behçet's disease,” Genes and Immunity, vol. 16, no. 2, pp. 170–175, 2015.
question,” *Clinical and Experimental Rheumatology*, vol. 34, supplement 95, no. 1, pp. S3–S4, 2016.

[191] E. Ben-Chetrit, “Behçet’s syndrome and pregnancy: course of the disease and pregnancy outcome,” *Clinical and Experimental Rheumatology*, vol. 32, supplement 84, no. 4, pp. S93–S98, 2014.

[192] S. Uzun, E. Alpsoy, M. Durdu, and A. Akman, “The clinical course of Behçet’s disease in pregnancy: a retrospective analysis and review of the literature,” *Journal of Dermatology*, vol. 30, no. 7, pp. 499–502, 2003.

[193] C. Iskender, O. Yasar, O. Kaymak, S. T. Yaman, D. Uygur, and N. Danisman, “Behçet’s disease and pregnancy: A retrospective analysis of course of disease and pregnancy outcome,” *Journal of Obstetrics and Gynaecology Research*, vol. 40, no. 6, pp. 1598–1602, 2014.

[194] N. Noel, B. Wechsler, J. Nizard et al., “Behçet’s disease and pregnancy,” *Arthritis and Rheumatism*, vol. 65, no. 9, pp. 2450–2456, 2013.

[195] S. Marsal, C. Falga, C. P. Simeon, M. Vilardell, and J. A. Bosch, “Behçet’s disease and pregnancy relationship study,” *Rheumatology*, vol. 36, no. 2, pp. 234–238, 1997.

[196] J. Jadaon, A. Shushan, Y. Ezra, H. Y. Sela, C. Ozcan, and N. Rojansky, “Behçet’s disease and pregnancy,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 84, no. 10, pp. 939–944, 2005.

[197] A. N. Gungor, G. Kalkan, S. Oguz, B. Sen, P. Ozoguz, Z. Takci et al., “Behçet disease and pregnancy,” *Clinical and Experimental Obstetrics and Gynecology*, vol. 41, pp. 617–619, 2014.